Precigen is a cash-burning biotech with a dangerously weak quality profile, but extreme momentum signals and analyst upside of 159% suggest a speculative setup with limited near-term downside if short-interest pressure resolves.
Thesis pillars
- Cash Burn Quality Floor Breach→Stable
- High Short Interest Risk↓Deteriorating
- Momentum Technical Breakout↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Precigen, Inc. (PGEN) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $7.75: Concentration risk — Product: Papzimeos; Near 52-week high (3.6% away).
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting... Read more
Sell if holding. Multiple concerning factors at $7.75: Concentration risk — Product: Papzimeos; Near 52-week high (3.6% away). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 4.4/10, high confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 48d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-09-25Recent Developments — Precigen, Inc.
Latest news
- NEWS This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday — benzinga Sep 25, 2026 neutral
- NEWS B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12 — benzinga Sep 25, 2026 positive
- NEWS Precigen Says FDA Granted Platform Technology Designation To AdenoVerse Immunotherapy Platform — benzinga Sep 21, 2026 positive
- NEWS Toast To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday — benzinga Aug 5, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18 — benzinga Aug 5, 2026 neutral
Generated 2026-09-25T20:57:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPapzimeos10-K Item 1A: 'Our near-term prospects, including our ability to develop our product candidates and generate revenue, and our future growth are substantially dependent on the commercial success of Papzimeos.'
Material Events(8-K, last 90d)
- 2026-06-24Item 5.02LOWStockholders approved an amendment to the 2023 Omnibus Incentive Plan at the June 18, 2026 Annual Meeting, increasing shares available for issuance by 7 million. Routine compensatory plan amendment; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $7.75: Concentration risk — Product: Papzimeos; Near 52-week high (3.6% away). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $7.21. Score 4.4/10, high confidence.
Take-profit target: $12.30 (+58.8% upside). Prior stop was $7.21. Stop-loss: $7.21.
Concentration risk — Product: Papzimeos; Near 52-week high (3.6% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0).
Precigen, Inc. trades at a P/E of N/A (forward -35.0). TrendMatrix value score: 0.0/10. Verdict: Sell.
9 analysts cover PGEN with a consensus score of 4.0/5. Average price target: $14.
What does Precigen, Inc. do?Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using...
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.